Evidence map›Paper›PMID 35628540›Full record

ReviewInternational journal of molecular sciences2022

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.

Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, Valeria Mazzi, Giovanni Guglielmi, Rudy Foddis and 4 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Is Melanoma Progression Affected by Thyroid Diseases?International journal of molecular sciences · 2022
    Review
  9. Article
  10. Targeting Melanin in Melanoma with Radionuclide Therapy.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Francesca RagusaDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Silvia Martina FerrariDepartment of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Giusy EliaDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Sabrina Rosaria PaparoDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Eugenia BalestriDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Chiara BotriniDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Armando PatrizioDepartment of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, 56124 Pisa, Italy.ORCID 0000-0003-1090-4794
Valeria MazziDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Giovanni GuglielmiU.O. Medicina Preventiva Del Lavoro, Azienda Ospedaliero-Universitaria Pisana, 56124 Pisa, Italy.
Rudy FoddisDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
Claudio SpinelliDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Salvatore UlisseDepartment of Surgical Sciences, 'Sapienza' University of Rome, 00161 Rome, Italy.ORCID 0000-0002-7573-0759
Alessandro AntonelliDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-5211-6342
Poupak FallahiDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer is the most common (~90%) type of endocrine-system tumor, accounting for 70% of the deaths from endocrine cancers. In the last years, the high-throughput genomics has been able to identify pathways/molecular targets involved in survival and tumor progression. Targeted therapy and immunotherapy individually have many limitations. Regarding the first one, although it greatly reduces the size of the cancer, clinical responses are generally transient and often lead to cancer relapse after initial treatment. For the second one, although it induces longer-lasting responses in cancer patients than targeted therapy, its response rate is lower. The individual limitations of these two different types of therapies can be overcome by combining them. Here, we discuss MAPK pathway inhibitors, i.e., BRAF and MEK inhibitors, combined with checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4. Several mutations make tumors resistant to treatments. Therefore, more studies are needed to investigate the patient's individual tumor mutation burden in order to overcome the problem of resistance to therapy and to develop new combination therapies.

Indexed as

MelanomaThyroid NeoplasmsHumansImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins B-rafBRAF protein, humanImmune Checkpoint InhibitorsProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins B-rafimmunotherapynew checkpoint inhibitorsPD-1 inhibitorsPD-L1 inhibitorsthyroid cancertyrosine kinase inhibitors

Identifiers

PMID35628540
PMCPMC9144613
OpenAlexW4280525915

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.